Pectus cancer statum
Singulis fere 10-12% aegroti cancer pectoris in mundo in India sunt, et fere duae tertiae partes aegrorum in tempore diagnosi cum cancro provectus dignoscuntur. Periti enucleati sunt 50,000 ad 60,000 HER2-positivum carcinomatis pectoris in India esse debere, et minus quam 20% aegrorum confirmatorum curationem anti-HER2 accepisse. "Hoc significat plus quam 80% aegrorum curatio iaculis non attingere, et optimae curationis opportunitates amittuntur."
According to the data, when receiving targeted therapy based on chemotherapy, the risk of recurrence of HER2-positive pectus cancer patients was reduced by about 40%, the risk of death was reduced by nearly 30%, and the ten-year survival rate was increased by more than 8%. At present, the treatment of breast cancer has entered the era of individualized and precise treatment. However, due to different detection levels and analysis levels, different testing institutions in China will give different test results, which will greatly affect the treatment results of patients.
Pectus cancer studio
Secundum eventus Universitatis "JAMA Oncologiae", periti Americani credunt: "Inventiones nostrae suggerunt eventus testium geneticorum significanter variari posse, secundum quod experimentum aegrotus applicat". Global Oncologist Periti Network aegros electae probatio geneticae institutionis subtilitatem experimenti quam maxime efficere posse, subtilitatem analyseos medicae clinicae et differentiam in curatione consequitur vitare.
In 2007 est, Acta de American Societas Oncology (ASCO) nuntiavit cancer pectus 21 gene probatio habenda pro aegris cum carcinomate pectoris primo qui positi sunt pro receptoribus estrogenis et nodos lymphos non sparserunt in progressu curationis cancri pectoris. In National Cancer Centre System (NCCN) usum cancri pectoris 21 testium generum in MMVIII curationis cancri pectoris sui protulerunt.
Breast cancer 21 gene test refers to the detection of the expression levels of 21 different genes in breast cancer tuberculum tissues, including 16 breast cancer-related genes and 5 reference genes. This test can provide individualized prediction of treatment effects and 10-year risk of recurrence. prediction. By detecting 21 genes and observing their interactions to determine tumor characteristics, the breast cancer recurrence index and the benefit ratio of chemotherapy can be predicted.
Breast cancer 21 gene test is mainly applicable to newly diagnosed breast cancer patients who are in stage I or II, positive for estrogen receptor, negative for lymph node metastasis, and will be treated with tamoxifen. After menopause, patients with aggressive lymphoma who are positive for lymph nodes and estrogen receptors can also use the 21 gene test to determine the benefit of chemotherapy.
Subtilitas curatio ad cancer pectus
Morbi non pretium turpis. Generaliter cancer mammae in quattuor species dividi potest: LuminalA, LuminalB, HER2, affirmativa, et tripla negativa secundum diversitatem indicibus ut ER, PR, HER2, Ki67. Luminales A et Luminales B sunt communissima subtypa hypothetica cancer pectoris, ac plusquam LX% omnium carcinomata pectoris, et bonum deploratum habent. Prognosis pro HER60 affirmativa et tripla negativa est relative pauper. Inter eos, HER2-positivus cancer pectoris valde periculosus est subtypus cancri pectoris, et circa 2% -20% aegros cancer pectoris sunt HER30-positivi. Secundum genotyping cancer mammae debitam curationem inveniunt et medicamenta iaculis.
Targeted pharmaca pro carcinomate
Trastuzumab (Herceptin) anno 1998 iactum est et in multis aegris cancer pectus positivum her2-positivum effectum habet. Eventus iudiciorum clinicorum suadeant ut therapiam trastuzumab adjuvante efficaciter et efficaciter reducere possit periculum recursu, plus HER2 Aegroti cum primis positivum carcinomati prodesse plus quam 10 annis. Lapatinib (Tykerb) Lapatinib est oralis, convertibilis inhibitor kinasus tyrosinus, qui utrumque tumorem cellae incrementi receptae epidermalis vetat (EGFR, HER1) et HER2 effectus tyrosinus phosphas insigniter melior est quam medicamenta quae unum tantum scutorum inhibent. Hoc pharmacum est alterum medicamentum hypotheticum iaculis probatum pro venalicium ad cancer pectoris post trastuzumab, maxime ad curationem cancri pectoris progressi. Bevacizumab (nomen artis Avastin) Recombinans anticorpus monoclonale humanatum quod impedit VEGF biologicum-mediatum actionem certatim obligans receptores VEGF cum factore endotheliali vasculari (VEGF), inhibito mitosis cellulis endothelialibus tumorem neovascularizationem minuit et effectum obtinet incrementi tumoris inhibitionis. . Angiogenesis tumorem inhibere primum medicamentum probatum est. Lenatinib (Neratinib / Noratinib) est oralis, immedicabilis HER1,2 et 4 inhibitor. Afatinib Afatinib est medicamentum orale parvum moleculum, quod effectus inhibendi inhibendi habet in HER1,2 et IV.
